Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | PAR 25 048

Frequently Asked Questions (FAQs)

What is the name of this funding opportunity?

The opportunity is titled "Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)" and is published as PAR-25-048 by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

What is the overall goal of PAR-25-048?

The goal is to support investigator-initiated, real-world, forward-looking (prospective) observational comparative effectiveness research (CER) in the clinical neurosciences. The intent is to generate evidence that can inform and improve current clinical practice by comparing the effectiveness of different clinical approaches used in routine care.

What does "comparative effectiveness research (CER)" mean in this announcement?

In this context, CER refers to studies that compare outcomes associated with different clinical approaches (for example, different preventive strategies, diagnostic approaches, or interventions) to help inform real clinical decisions. The comparison is based on observing what happens in routine practice rather than assigning interventions as part of the study.

Is this opportunity for clinical trials?

No. This opportunity is explicitly for observational CER and is labeled "Clinical Trial Not Allowed." The study design should not involve assigning participants to interventions as part of the research. Instead, investigators observe and analyze outcomes associated with care that patients and clinicians are already receiving or choosing as part of routine clinical practice.

What kinds of clinical approaches or interventions can be evaluated?

The scope is broad and may include preventive strategies, diagnostic approaches, and interventions used in routine care. Examples mentioned include drugs, biologics, medical devices, surgical approaches, behavioral treatments, and rehabilitation therapies, as long as the central research questions align with the NINDS mission and research priorities.

What does "prospective observational" mean for this program?

It means the study is forward-looking and collects or tracks information over time while observing real-world care and outcomes. The research is designed to follow participants and capture outcomes as they occur, without the study assigning the intervention being received.

What mechanism is used to fund projects under this announcement?

Projects are supported under a cooperative agreement mechanism using a two-phase UG3/UH3 model. Cooperative agreements typically involve more programmatic involvement from NIH/NINDS than a standard research grant.

How is the UG3/UH3 award structured?

The award has two phases submitted as a single, integrated application. The first phase (UG3) is a milestone-driven planning period of up to two years. The second phase (UH3) can provide up to five years of support to conduct the full-scale prospective observational study.

What is the purpose of the UG3 phase?

The UG3 phase is intended to reduce risk and ensure feasibility before launching the full observational study. It supports scientific and operational planning activities, including small-scale data collection to test feasibility and acceptability of key study elements and to refine study operations and infrastructure.

What kinds of activities are expected during the UG3 planning phase?

Examples listed include small-scale data collection to test feasibility and acceptability of data collection methods, data storage processes, and the planned analytic approach. Operational planning activities include developing recruitment and retention strategies, creating case report forms, and building or refining the data management system and other tools needed for data and quality management.

Is transition from UG3 to UH3 automatic?

No. Transition is not automatic. Only projects that meet predefined scientific milestones and feasibility requirements are eligible to move forward to the UH3 phase.

What happens during the UH3 phase?

The UH3 phase is the full-scale execution phase (up to five years). This is when enrollment, follow-up, data capture, and primary analyses occur, guided by the infrastructure and protocols established during the UG3 phase.

How does a cooperative agreement affect how the project is managed?

Because this is a cooperative agreement, awardees should expect more substantial programmatic involvement from NIH/NINDS compared with a standard research grant. The summary emphasizes involvement around milestones, progress oversight, and adherence to agreed-upon plans for study conduct and data quality.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include (as described in the summary) various levels of government entities, public and private institutions of higher education, tribal governments and tribal organizations, nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and other entities.

Are non-U.S. (foreign) organizations eligible?

Yes. The summary explicitly includes eligibility for non-U.S. (foreign) organizations.

Are U.S. territories or possessions included in eligibility?

Yes. The summary explicitly highlights eligibility for U.S. territories or possessions.

Does the announcement highlight eligibility for historically underrepresented or community-based institutions?

Yes. The summary explicitly highlights eligibility for a range of community-based and historically underrepresented institution types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and regional organizations, among others.

What NIH institute is sponsoring this opportunity?

The sponsoring institute is the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH).

What clinical and research areas does NINDS expect proposals to address?

The proposed study questions should align with the NINDS mission and research priorities (as described on the NINDS website). The announcement is focused on clinical neurosciences and neurology-related areas.

What is the CFDA/Assistance Listing number associated with this program area?

The CFDA/Assistance Listing number referenced in the summary is 93.853.

What type of funding is this categorized as?

The opportunity is categorized as discretionary funding, and the funding instrument is a cooperative agreement.

When is the closing date listed in the summary?

The original closing date listed is 2025-09-07.

What is the opportunity record creation date shown in the summary?

The opportunity record indicates a creation date of 2025-01-08.

Does the posted summary provide an award ceiling or the expected number of awards?

No. The posted summary does not specify an award ceiling or the expected number of awards. The summary indicates that applicants typically need to consult the full funding opportunity announcement and related NIH guidance for budget expectations, institute-specific constraints, and any additional review or submission requirements.

What kind of orientation does NINDS emphasize for these studies?

The summary emphasizes a practical, real-world orientation. Proposed studies should be a cost-effective way to collect data with meaningful bearing on real clinical decisions, rather than being primarily exploratory or detached from everyday care.

Can the observational CER include interventions like devices, surgery, or rehabilitation?

Yes. The summary explicitly states that studies may evaluate drugs, biologics, medical devices, surgical approaches, behavioral treatments, and rehabilitation therapies, provided the research is observational CER and aligns with NINDS priorities.